Table 10.
Signs and symptoms at end of study in evaluable patients (mITT) (n = 154)*
| Signs and symptoms | Cefditoren pivoxil (75) (%) | Cefdinir (79) (%) |
|---|---|---|
| Fever | ||
| Present | 5 (6.67) | 5 (6.33) |
| Absent | 70 (93.33) | 74 (93.67) |
| Chills | ||
| Present | 0 (0) | 2 (2.53) |
| Absent | 75 (100) | 77 (97.47) |
| Malaise | ||
| Present | 0 (0) | 3 (3.80) |
| Absent | 75 (100) | 76 (96.20) |
| Pruritus | ||
| Present | 5 (6.67) | 7 (8.86) |
| Absent | 70 (93.33) | 72 (91.14) |
| Pain at the site of lesion(s) | ||
| Present | 5 (6.67) | 6 (7.59) |
| Absent | 70 (93.33) | 73 (92.41) |
| Erythema around the lesion(s) | ||
| Present | 5 (6.67) | 3 (3.80) |
| Absent | 70 (93.33) | 76 (96.20) |
| Tenderness | ||
| Present | 5 (6.67) | 5 (6.33) |
| Absent | 70 (93.33) | 74 (93.67) |
| Regional lymphadenopathy | ||
| Present | 1 (1.33) | 3 (3.80) |
| Absent | 74 (98.67) | 76 (96.20) |
| Ulceration of lesion(s) | ||
| Present | 5 (6.67) | 4 (5.06) |
| Absent | 70 (93.33) | 74 (93.67) |
| Discharge from lesion(s) | ||
| Present | 5 (6.67) | 4 (5.06) |
| Absent | 70 (93.33) | 75 (94.94) |
| Crust/Scab formation | ||
| Present | 19 (25.33) | 24 (30.38) |
| Absent | 56 (74.67) | 55 (69.62) |
| Induration | ||
| Present | 4 (5.33) | 4 (5.06) |
| Absent | 71 (94.67) | 75 (94.94) |
| Lesions completely healed | ||
| Present | 55 (73.33) | 59 (74.68) |
| Absent | 20 (26.67) | 20 (25.32) |
| Lesions partially healed | ||
| Present | 15 (20.00) | 17 (21.52) |
| Absent | 59 (78.67) | 62 (78.48) |
| New lesions | ||
| Present | 0 (0) | 2 (2.53) |
| Absent | 75 (100) | 77 (97.47) |
*
Data missing for ‘lesions partially healed’ for 1 patient in cefditoren pivoxil group & for ‘ulceration’ for 1 patient in cefdinir group